Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company developing the oral CETP inhibitor obicetrapib for LDL-C lowering in patients at risk of cardiovascular disease. Through these regulatory documents, investors can review how NewAmsterdam reports its clinical progress, financial position and corporate actions.
Current reports on Form 8-K are used by NewAmsterdam to disclose material events such as quarterly financial results, corporate updates and the publication of investor presentations. For example, the company has filed an 8-K to furnish a press release announcing financial results for a recent quarter and to make an updated corporate investor presentation available as an exhibit. Such filings can give context on research and development spending, cash and marketable securities, and the status of key clinical and regulatory milestones.
NewAmsterdam also uses SEC filings to document equity-related matters, including inducement share option grants made under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). These disclosures outline the size of option grants, vesting schedules and exercise prices for new hires, providing insight into compensation practices and share-based incentives.
On Stock Titan, NewAmsterdam’s SEC filings are updated as they are made available from EDGAR, and AI-powered tools can help summarize lengthy documents, highlight key sections and clarify terminology. Users can quickly locate quarterly and annual reports when filed, review 8-Ks describing clinical and regulatory developments, and examine exhibits such as press releases and corporate presentations. This makes it easier to understand how NewAmsterdam communicates the evolution of its obicetrapib program, its collaboration and licensing arrangements, and other corporate information in its official regulatory record.
NewAmsterdam Pharma Co N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported stock option exercises and related share sales. On January 20 and 21, 2026, he exercised options to acquire 60,216 and 39,784 ordinary shares at an exercise price of
After these transactions, Somaiya directly held 58,382 ordinary shares and 662,814 option-based derivative securities. The filing states that at least one sale transaction was carried out under a Rule 10b5-1 trading plan, and notes that the underlying option was granted on
NAMS reported that an affiliated holder has filed a Rule 144 notice to sell 200,000 ordinary shares through J.P. Morgan Securities LLC on or about 01/20/2026 on Nasdaq. The planned sale has an indicated aggregate market value of $6,330,000. The seller acquired the 200,000 shares from the issuer on the same date via a stock option exercise paid in cash. The filing also lists 113,390,804 ordinary shares outstanding for the issuer, providing context for the size of this planned transaction.
NewAmsterdam Pharma Co N.V. director Hilde Johanna van der Kamp reported new equity awards. On January 7, 2026, she received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration and scheduled to vest in full on the one-year anniversary of the vesting start date, subject to continued service. She also received an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share, with all option shares vesting on January 2, 2027, also conditioned on continued service.
NewAmsterdam Pharma Co. N.V. director Adele M. Gulfo reported equity awards in the form of ordinary shares and options. On January 7, 2026, she received 3,400 restricted stock units (RSUs)14,260. The RSUs were granted for no cash consideration and will fully vest on the one-year anniversary of the vesting start date, subject to her continued service.
On the same date, she was also granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share, with 15,300 options owned following the grant. All shares underlying the option are scheduled to vest on January 2, 2027, also conditioned on her continued service.
NewAmsterdam Pharma Co N.V.'s Chief Executive Officer and director Michael H. Davidson reported several equity transactions dated January 7, 2026. He sold 11,582 ordinary shares in a pre-arranged sell-to-cover transaction used solely to satisfy tax withholding on vesting restricted stock units, at a weighted average price between $35.24 and $35.59 per share. After this sale, he directly owned 378,859 ordinary shares.
On the same date, he acquired 81,000 restricted stock units (RSUs), each representing one ordinary share. These RSUs were granted for no consideration and are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the vesting start date, contingent on his continued service. He was also granted an option to buy 364,000 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036, with 25% vesting on January 2, 2027 and the remainder vesting monthly over the following three years, subject to continued service.
NewAmsterdam Pharma Co. N.V. director William Lewis reported equity awards from the company. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing a contingent right to one ordinary share, granted for no cash consideration. All of these RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares, with all underlying shares scheduled to vest on January 2, 2027, also conditioned on continued service. Following the RSU grant, Lewis beneficially owned 10,360 ordinary shares directly.
NewAmsterdam Pharma Co. N.V. director John W. Smither reported equity compensation awards. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration. All RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share. These option shares will vest on January 2, 2027, the one-year anniversary of the vesting start date, if he continues in service. After these transactions, he directly owns 10,360 ordinary shares and 15,300 options.
NewAmsterdam Pharma Co. N.V. reported that director Mark C. McKenna received new equity awards. On January 7, 2026, he was granted 3,400 restricted stock units (RSUs), each representing the right to receive one ordinary share. These RSUs will vest in full on the one-year anniversary of the vesting start date, conditioned on his continued service. They were granted for no cash consideration, and following this award he beneficially owns 10,360 ordinary shares directly.
On the same date, McKenna also received an option to acquire 15,300 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036. All shares underlying this option will vest on January 2, 2027, also subject to his continued service, leaving him with 15,300 derivative securities beneficially owned.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported equity awards granted on January 7, 2026. He received 3,400 restricted stock units, each representing a contingent right to one ordinary share, granted for no consideration and scheduled to vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share. All shares underlying this option are scheduled to vest on January 2, 2027, also contingent on continued service. Following these awards, he beneficially owned 10,360 ordinary shares and 15,300 options directly.
NewAmsterdam Pharma Company N.V. furnished an update on its financial position and recent progress. The company reported that unaudited cash, cash equivalents and marketable securities totaled approximately $729 million as of December 31, 2025, providing a view of its liquidity at year-end. This figure was shared in a press release that also highlighted the company’s 2025 achievements and outlined its strategic priorities for 2026.
The press release is included as an exhibit to the report and is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.